UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 18

of 'Overview of skin testing for allergic disease'

18
TI
Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.
AU
Noga O, Hanf G, Kunkel G
SO
Int Arch Allergy Immunol. 2003;131(1):46.
 
IgE plays a key role in allergic asthma. We investigated whether omalizumab treatment of patients with moderate to severe allergic asthma leads to changes in inflammatory mediators and clinical symptoms. This sub-study was conducted on 35 patients with a positive skin prick test (SPT) requiring daily administration of beclomethasone dipropionate (500-1,000 microg), who participated in a multicentre, randomised, double-blind, placebo-controlled study. Omalizumab or placebo was administered at 0.016 mg/kg/IgE every 4 weeks. Patients recorded peak expiratory flow, asthma symptom score and beta(2)-agonist use in daily diaries and spirometry was performed at each visit. beta(2)-Agonist use and SPT wheal reaction decreased significantly (p<0.05). Circulating levels of IL-5, IL-6, IL-8, IL-10, IL-13 and s-ICAM were measured before and after 16 weeks of treatment. IL-13 and s-ICAM were measured before and after 16 weeks of treatment. IL-13 decreased significantly (p<0.01). IL-5 and IL-8 decreased in the omalizumab group compared to baseline. The other circulating mediators did not demonstrate any changes. Histamine release was significantly reduced (p<0.01). Airway resistance (p<0.05) and the provocative concentration inducing a 20% decrease in FEV(1) (p<0.05) were measured before, after 16 weeks, and 3 months after completion of treatment. Both parameters decreased significantly (p<0.05). Peripheral eosinophil count decreased significantly compared to placebo (p<0.01). These findings suggest that omalizumab has potential as a novel treatment for allergic asthma.
AD
Allergy and Asthma Clinic, Charité, Humboldt University, Berlin, Germany. oliver.nago@charite.de
PMID